Oppenheimer Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $26
Alumis Analyst Ratings
Promising Efficacy of Alumis Inc.'s ESK-001 in Psoriasis Treatment Boosts Market Position and Buy Rating
Leerink Partners Maintains Alumis(ALMS.US) With Buy Rating
Promising Developments in Alumis Inc.'s Clinical Programs Support Buy Rating
Oppenheimer Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $26
Alumis Inc. (ALMS) Gets a Buy From Oppenheimer
Alumis Analyst Ratings
H.C. Wainwright Maintains Alumis(ALMS.US) With Buy Rating, Maintains Target Price $19
Analysts Offer Insights on Materials Companies: Alumis Inc. (ALMS) and Martin Marietta Materials (MLM)
Oppenheimer Maintains Alumis(ALMS.US) With Buy Rating, Cuts Target Price to $26
Oppenheimer Reaffirms Their Buy Rating on Alumis Inc. (ALMS)
Baird Maintains Alumis(ALMS.US) With Buy Rating, Cuts Target Price to $17
Alumis Analyst Ratings
HC Wainwright & Co. Maintains Buy on Alumis, Lowers Price Target to $19
H.C. Wainwright Maintains Alumis(ALMS.US) With Buy Rating, Cuts Target Price to $19
Oppenheimer Initiates Alumis(ALMS.US) With Buy Rating, Announces Target Price $32
Alumis Analyst Ratings
Analysts Offer Insights on Materials Companies: Alumis Inc. (ALMS) and Corning (GLW)
Oppenheimer Initiates Coverage on Alumis With Outperform Rating, $32 Price Target